Compare · MIRM vs RVPH
MIRM vs RVPH
Side-by-side comparison of Mirum Pharmaceuticals Inc. (MIRM) and Reviva Pharmaceuticals Holdings Inc. (RVPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MIRM and RVPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MIRM is the larger of the two at $5.71B, about 1265.2x RVPH ($4.5M).
- Over the past year, MIRM is up 98.5% and RVPH is down 97.9% - MIRM leads by 196.4 points.
- MIRM has been more active in the news (16 items in the past 4 weeks vs 1 for RVPH).
- MIRM has more recent analyst coverage (25 ratings vs 6 for RVPH).
- Company
- Mirum Pharmaceuticals Inc.
- Reviva Pharmaceuticals Holdings Inc.
- Price
- $93.46-0.07%
- $0.36-55.68%
- Market cap
- $5.71B
- $4.5M
- 1M return
- -9.24%
- -58.40%
- 1Y return
- +98.51%
- -97.90%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 16
- 1
- Recent ratings
- 25
- 6
Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company was incorporated in 2018 and is headquartered in Foster City, California.
Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 that has completed Phase II clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials for treating bipolar disorder, major depressive disorder, behavioral and psychotic symptoms, dementia or Alzheimer's disease, parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis; and RP1208 that has completed pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.
Latest MIRM
- PRESIDENT AND COO Radovich Peter exercised 16,988 shares at a strike of $19.19, increasing direct ownership by 42% to 57,260 units (SEC Form 4)
- SEC Form 144 filed by Mirum Pharmaceuticals Inc.
- Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
- Director Cardon Lon converted options into 3,977 shares, increasing direct ownership by 70% to 9,680 units (SEC Form 4)
- CHIEF EXECUTIVE OFFICER Peetz Christopher exercised 30,000 shares at a strike of $2.94 and sold $2,875,103 worth of shares (30,000 units at $95.84) as part of a pre-agreed trading plan (SEC Form 4)
- Director Walbert Timothy P converted options into 3,977 shares, increasing direct ownership by 70% to 9,680 units (SEC Form 4)
- Director Fischer Laurent converted options into 3,977 shares, increasing direct ownership by 59% to 10,727 units (SEC Form 4)
- Director Ramasastry Saira converted options into 3,977 shares and sold $397,700 worth of shares (3,977 units at $100.00) as part of a pre-agreed trading plan (SEC Form 4)
- Citigroup initiated coverage on Mirum Pharmaceuticals with a new price target
- SEC Form 144 filed by Mirum Pharmaceuticals Inc.
Latest RVPH
- Reviva to Participate in Fireside Chat at A.G.P.'s Annual Healthcare Company Showcase
- Amendment: SEC Form SCHEDULE 13G/A filed by Reviva Pharmaceuticals Holdings Inc.
- SEC Form SCHEDULE 13G filed by Reviva Pharmaceuticals Holdings Inc.
- SEC Form 10-Q filed by Reviva Pharmaceuticals Holdings Inc.
- Reviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
- Reviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events
- SEC Form SCHEDULE 13G filed by Reviva Pharmaceuticals Holdings Inc.
- Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine's Potential Across Multiple Neuropsychiatric Indications
- Reviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits